{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:34:13Z","timestamp":1787697253530,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi Colombia S.A and IPSEN Export Latin America","doi-asserted-by":"publisher","award":["E003183552"],"award-info":[{"award-number":["E003183552"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013367","name":"Technological University of Pereira","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Acromegaly and neuroendocrine tumors are rare diseases that, under certain conditions, can be treated with somatostatin analogs. The aim was to determine the prescription patterns of somatostatin analogs in a group of patients with acromegaly and neuroendocrine tumors affiliated with the Colombian Health System.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective study. A cohort of patients from a drug dispensing database that collected all prescriptions of long-acting somatostatin analogs (octreotide, lanreotide, pasireotide). Sociodemographic variables, clinical variables (diagnosis and comorbidities) and pharmacological therapy variables (dose, changes, persistence of use, comedications) were considered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 213 patients were identified, including 139 (65.3%) with acromegaly and 74 (34.7%) with neuroendocrine tumors. There was a predominance of women (58.7%) and a mean age of 59.7\u2009\u00b1\u200914.5\u00a0years. The most commonly used medications were lanreotide autogel (<jats:italic>n<\/jats:italic>\u2009=\u2009107; 50.2%), octreotide LAR (<jats:italic>n<\/jats:italic>\u2009=\u2009102; 47.9%) and pasireotide LAR (<jats:italic>n<\/jats:italic>\u2009=\u20094; 1.9%). During follow-up, 11.3% of patients experienced modifications of therapy, with a mean duration from the beginning of treatment to the change in medication of 25\u2009\u00b1\u200915.9\u00a0months. A total of 48.9% of the patients with acromegaly and 87.1% of individuals with neuroendocrine tumors received maximum approved doses of the drug.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with acromegaly and neuroendocrine tumors in Colombia are mainly women and are most frequently treated with lanreotide autogel for acromegaly and with octreotide LAR for neuroendocrine tumors. In addition, a high proportion are managed with maximum doses of long-acting somatostatin analogs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-022-01875-7","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T05:04:52Z","timestamp":1659330292000},"page":"27-35","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-0936","authenticated-orcid":false,"given":"J. E.","family":"Machado-Alba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8458-0986","authenticated-orcid":false,"given":"M. E.","family":"Machado-Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2500-7658","authenticated-orcid":false,"given":"A.","family":"Gaviria-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. N.","family":"Arsof-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Castellanos-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Botero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Triana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"1875_CR1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.beem.2009.05.010","volume":"23","author":"P Chanson","year":"2009","unstructured":"Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J (2009) Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab 23:555\u2013574. https:\/\/doi.org\/10.1016\/j.beem.2009.05.010","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1875_CR2","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1172\/JCI39375","volume":"119","author":"S Melmed","year":"2009","unstructured":"Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189\u20133202. https:\/\/doi.org\/10.1172\/JCI39375","journal-title":"J Clin Invest"},{"key":"1875_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11102-011-0310-7","volume":"14","author":"A Ben-Shlomo","year":"2011","unstructured":"Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S (2011) Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14:284\u2013294. https:\/\/doi.org\/10.1007\/s11102-011-0310-7","journal-title":"Pituitary"},{"key":"1875_CR4","doi-asserted-by":"publisher","first-page":"T141","DOI":"10.1530\/JOE-15-0109","volume":"226","author":"C Capatina","year":"2015","unstructured":"Capatina C, Wass JA (2015) 60 YEARS OF NEUROENDOCRINOLOGY: acromegaly. J Endocrinol 226:T141\u2013T160. https:\/\/doi.org\/10.1530\/JOE-15-0109","journal-title":"J Endocrinol"},{"key":"1875_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/MED.0b013e328354af67","volume":"19","author":"LF Grasso","year":"2012","unstructured":"Grasso LF, Pivonello R, Colao A (2012) Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate? Curr Opin Endocrinol Diabetes Obes 19:288\u2013294. https:\/\/doi.org\/10.1097\/MED.0b013e328354af67","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1875_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s11102-009-0206-y","volume":"13","author":"A Barkan","year":"2010","unstructured":"Barkan A, Bronstein MD, Bruno OD, Cob A, Espinosa-de-los-Monteros AL, Gadelha MR, Garavito G, Guitelman M, Mangupli R, Mercado M, Portocarrero L, Sheppard M (2010) Management of acromegaly in Latin America: expert panel recommendations. Pituitary 13:168\u2013175. https:\/\/doi.org\/10.1007\/s11102-009-0206-y","journal-title":"Pituitary"},{"key":"1875_CR7","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1007\/s11102-013-0531-z","volume":"17","author":"MD Bronstein","year":"2014","unstructured":"Bronstein MD, Bruno OD, Abreu A, Mangupli R, Mercado M (2014) A practical approach to acromegaly management in Latin America. Pituitary 17:S30\u2013S35. https:\/\/doi.org\/10.1007\/s11102-013-0531-z","journal-title":"Pituitary"},{"key":"1875_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11102-010-0269-9","volume":"14","author":"A Giustina","year":"2011","unstructured":"Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S (2011) Current management practices for acromegaly: an international survey. Pituitary 14:125\u2013133. https:\/\/doi.org\/10.1007\/s11102-010-0269-9","journal-title":"Pituitary"},{"key":"1875_CR9","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3:1335\u20131342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589","journal-title":"JAMA Oncol"},{"key":"1875_CR10","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1186\/s12885-019-6412-8","volume":"19","author":"J Darb\u00e0","year":"2019","unstructured":"Darb\u00e0 J, Mars\u00e0 A (2019) Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources. BMC Cancer 19:1226. https:\/\/doi.org\/10.1186\/s12885-019-6412-8","journal-title":"BMC Cancer"},{"key":"1875_CR11","unstructured":"Fagnani F, Feuilly M, Marteau F, de Z\u00e9licourt M, Kamenicky P, de Mestier L. Lanreotide autogel and octreotide LAR treatment patterns: results from a nationwide French retrospective study. 17th Annual ENETS Conference | 11\u201313 March 2020; Barcelona, Spain.2020. https:\/\/www.enets.org\/lanreotide-autogel-and-octreotide-lar-treatment-patterns-results-from-a-nationwide-french-retrospective-study.html Accessed on Mar 1 2022."},{"key":"1875_CR12","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/ijms21051682","volume":"21","author":"M Gomes-Porras","year":"2020","unstructured":"Gomes-Porras M, C\u00e1rdenas-Salas J, \u00c1lvarez-Escol\u00e1 C (2020) Somatostatin analogs in clinical practice: a Review. Int J Mol Sci 21:1682. https:\/\/doi.org\/10.3390\/ijms21051682","journal-title":"Int J Mol Sci"},{"key":"1875_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/bjc.1998.101","volume":"77","author":"O Nilsson","year":"1998","unstructured":"Nilsson O, K\u00f6lby L, W\u00e4ngberg B, Wigander A, Billig H, William-Olsson L, Fj\u00e4lling M, Forssell-Aronsson E, Ahlman H (1998) Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 77:632\u2013637. https:\/\/doi.org\/10.1038\/bjc.1998.101","journal-title":"Br J Cancer"},{"key":"1875_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228\u2013252. https:\/\/doi.org\/10.1016\/j.yfrne.2013.07.005","journal-title":"Front Neuroendocrinol"},{"key":"1875_CR15","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.path.2019.08.011","volume":"12","author":"K Perez","year":"2019","unstructured":"Perez K, Chan J (2019) Treatment of gastroenteropancreatic neuroendocrine tumors. Surg Pathol Cli 12:1045\u20131053. https:\/\/doi.org\/10.1016\/j.path.2019.08.011","journal-title":"Surg Pathol Cli"},{"key":"1875_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40360-017-0124-y","volume":"18","author":"MH Gurel","year":"2017","unstructured":"Gurel MH, Han Y, Stevens AL, Furtado A, Cox D (2017) Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis. BMC Pharmacol Toxicol 18:22. https:\/\/doi.org\/10.1186\/s40360-017-0124-y","journal-title":"BMC Pharmacol Toxicol"},{"key":"1875_CR17","doi-asserted-by":"publisher","first-page":"205031211769479","DOI":"10.1177\/2050312117694795","volume":"5","author":"JE Machado-Alba","year":"2017","unstructured":"Machado-Alba JE, Machado-Duque ME (2017) Prescription patterns of long-acting somatostatin analogues. SAGE Open Med 5:2050312117694795. https:\/\/doi.org\/10.1177\/2050312117694795","journal-title":"SAGE Open Med"},{"key":"1875_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","volume":"182","author":"A Colao","year":"2020","unstructured":"Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol 182:583. https:\/\/doi.org\/10.1530\/EJE-19-0762","journal-title":"Eur J Endocrinol"},{"key":"1875_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Res\u00e9ndiz K, Ruffin M, Chen Y, Sheppard M, Pasireotide C2305 Study Group (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99:791\u2013799. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"key":"1875_CR20","unstructured":"Adigun OO, Nguyen M, Fox TJ, Anastasopoulou C. Acromegaly. StatPearls. Treasure Island (FL): Statpearls Publishing Copyright\u00a9 2021, StatPearls Publishing LLC; 2021. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK431086\/. Accessed on Mar 1 2022."},{"key":"1875_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12020-020-02206-7","volume":"68","author":"MR Ambrosio","year":"2020","unstructured":"Ambrosio MR, Gagliardi I, Chiloiro S, Ferreira AG, Bondanelli M, Giampietro A, Bianchi A, Marinis L, Fleseriu M, Zatelli MC (2020) Acromegaly in the elderly patients. Endocrine 68:16\u201331. https:\/\/doi.org\/10.1007\/s12020-020-02206-7","journal-title":"Endocrine"},{"key":"1875_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.dld.2020.08.031","volume":"53","author":"V Andreasi","year":"2021","unstructured":"Andreasi V, Partelli S, Muffatti F, Manzoni MF, Capurso G, Falconi M (2021) Update on gastroenteropancreatic neuroendocrine tumors. Dig Liver Dis 53:171\u2013182. https:\/\/doi.org\/10.1016\/j.dld.2020.08.031","journal-title":"Dig Liver Dis"},{"issue":"1","key":"1875_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ecl.2010.12.005","volume":"40","author":"B Lawrence","year":"2011","unstructured":"Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40(1):1\u201318. https:\/\/doi.org\/10.1016\/j.ecl.2010.12.005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1875_CR24","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1200\/JCO.2014.60.2532","volume":"33","author":"PL Kunz","year":"2015","unstructured":"Kunz PL (2015) Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol 33:1855\u20131863. https:\/\/doi.org\/10.1200\/JCO.2014.60.2532","journal-title":"J Clin Oncol"},{"key":"1875_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1365-2265.2009.03626.x","volume":"72","author":"TJ Reid","year":"2010","unstructured":"Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 72:203\u2013208. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03626.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1875_CR26","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.3748\/wjg.v26.i28.4036","volume":"26","author":"GB Mpilla","year":"2020","unstructured":"Mpilla GB, Philip PA, El-Rayes B, Azmi AS (2020) Pancreatic neuroendocrine tumors: therapeutic challenges and research limitations. World J Gastroenterol 26:4036\u20134054. https:\/\/doi.org\/10.3748\/wjg.v26.i28.4036","journal-title":"World J Gastroenterol"},{"key":"1875_CR27","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1677\/ERC-09-0042","volume":"16","author":"A Ahmed","year":"2009","unstructured":"Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16:885\u2013894. https:\/\/doi.org\/10.1677\/ERC-09-0042","journal-title":"Endocr Relat Cancer"},{"key":"1875_CR28","doi-asserted-by":"publisher","first-page":"e14265","DOI":"10.7759\/cureus.14265","volume":"13","author":"FS Alhawyan","year":"2021","unstructured":"Alhawyan FS (2021) Mortality in acromegalic patients: etiology, trends, and risk factors. Cureus 13:e14265. https:\/\/doi.org\/10.7759\/cureus.14265","journal-title":"Cureus"},{"key":"1875_CR29","doi-asserted-by":"publisher","first-page":"640999","DOI":"10.3389\/fonc.2021.640999","volume":"11","author":"H Yang","year":"2021","unstructured":"Yang H, Tan H, Huang H, Li J (2021) Advances in research on the cardiovascular complications of acromegaly. Front Oncol 11:640999. https:\/\/doi.org\/10.3389\/fonc.2021.640999","journal-title":"Front Oncol"},{"key":"1875_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1387","volume":"4","author":"K Ni","year":"2021","unstructured":"Ni K, Yang JY, Baeg K, Leiter AC, Mhango G, Gallagher EJ et al (2021) Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: a surveillance, epidemiology, and end results-medicare analysis of 5235 patients. Cancer Rep (Hoboken) 4:e1387. https:\/\/doi.org\/10.1002\/cnr2.1387","journal-title":"Cancer Rep (Hoboken)"},{"key":"1875_CR31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02566","author":"A Cozzolino","year":"2018","unstructured":"Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E, Gianfrilli D, Pasqualetti P, Lenzi A, Isidori AM (2018) Somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2017-02566","journal-title":"J Clin Endocrinol Metab"},{"key":"1875_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1708\/1319.14626","volume":"48","author":"P Moretti","year":"2013","unstructured":"Moretti P, Dennis JL, Stella A, Alpini A, Cotichelli P, Ferolla P, Scarpelli G, Quartesan R, Piselli M (2013) Comorbilit\u00e0 di ansia e depressione nei pazienti con tumori carcinoidi [Comorbility between anxiety and depression in patients with carcinoid tumors]. Riv Psichiatr 48:301\u2013306. https:\/\/doi.org\/10.1708\/1319.14626","journal-title":"Riv Psichiatr"},{"key":"1875_CR33","unstructured":"Ministerio de Salud y Protecci\u00f3n Social. Plan de beneficios en salud. Resoluci\u00f3n 2292 de 2021 y sus anexos. Bogot\u00e1. Colombia.2021. https:\/\/www.minsalud.gov.co\/Normatividad_Nuevo\/Resoluci%C3%B3n%20No.%202292%20de%202021.pdf"},{"key":"1875_CR34","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","volume":"99","author":"JD Carmichael","year":"2014","unstructured":"Carmichael JD, Bonert VS, Nu\u00f1o M, Ly D, Melmed S (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 99:1825\u20131833. https:\/\/doi.org\/10.1210\/jc.2013-3757","journal-title":"J Clin Endocrinol Metab"},{"key":"1875_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000377704","volume":"103","author":"P Chanson","year":"2016","unstructured":"Chanson P (2016) Medical treatment of acromegaly with dopamine agonists or somatostatin analogs. Neuroendocrinology 103:50\u201358. https:\/\/doi.org\/10.1159\/000377704","journal-title":"Neuroendocrinology"},{"key":"1875_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1530\/EJE-07-0488","volume":"158","author":"CL Ronchi","year":"2008","unstructured":"Ronchi CL, Rizzo E, Lania AG, Pivonello R, Grottoli S, Colao A, Ghigo E, Spada A, Arosio M, Beck-Peccoz P (2008) Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol 158:19\u201325. https:\/\/doi.org\/10.1530\/EJE-07-0488","journal-title":"Eur J Endocrinol"},{"key":"1875_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/EJE-11-0738","volume":"166","author":"C Ram\u00edrez","year":"2012","unstructured":"Ram\u00edrez C, Vargas G, Gonz\u00e1lez B, Grossman A, R\u00e1bago J, Sosa E, Espinosa-de-Los-Monteros AL, Mercado M (2012) Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol 166:21\u201326. https:\/\/doi.org\/10.1530\/EJE-11-0738","journal-title":"Eur J Endocrinol"},{"key":"1875_CR38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/13696998.2018.1474748","volume":"21","author":"MS Broder","year":"2018","unstructured":"Broder MS, Cai B, Chang E, Yan T, Benson AB 3rd (2018) First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA. J Med Econ 21:821\u2013826. https:\/\/doi.org\/10.1080\/13696998.2018.1474748","journal-title":"J Med Econ"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01875-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01875-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01875-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T15:24:19Z","timestamp":1673623459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01875-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["1875"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01875-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,1]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LB, LT, CC are employees of Sanofi-Aventis Colombia, and may hold shares and\/or stock options in the company. IA is an employee of Ipsen. JEMA, AGM and MEMD are employees of Audifarma and Universidad Tecnologica de Pereira and do not have any other conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the Bioethics Committee of the Universidad Tecnol\u00f3gica de Pereira (Technological University of Pereira) in the category of risk-free research (Code: 20 - 150321). The ethical principles established by the Declaration of Helsinki were respected.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The information was obtained from an administrative database. According to Colombian\u00a0regulations (Resolution 8430 of 1993 of the Ministry of Health) for risk-free research in which patients are not\u00a0interviewed, it is not required to sign an informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}